<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686657</url>
  </required_header>
  <id_info>
    <org_study_id>RK-01 Prototype</org_study_id>
    <nct_id>NCT03686657</nct_id>
  </id_info>
  <brief_title>Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients</brief_title>
  <acronym>RESILIENCE</acronym>
  <official_title>A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARKAY Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ARKAY Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual&#xD;
      add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes&#xD;
      patients with high blood pressure, arthritis and inadequate glycemic control with metformin&#xD;
      monotherapy, diet and exercise over 26 weeks of treatment.&#xD;
&#xD;
      Objective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin&#xD;
      resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to&#xD;
      metformin monotherapy.&#xD;
&#xD;
      Hypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR&#xD;
      provides greater improvements in glycemic, inflammatory and atherogenic parameters compared&#xD;
      to metformin monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY:&#xD;
&#xD;
      In patients with type 2 diabetes with inadequate glycemic control with metformin monotherapy:&#xD;
&#xD;
      Objective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin&#xD;
      resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to&#xD;
      metformin monotherapy. Improvements in glycemic, inflammatory and atherogenic parameters&#xD;
      including beta cell function relative to adult healthy volunteers with normal glucose&#xD;
      tolerance (NGT) treated with placebo for 26 weeks will also be assessed. An interim study&#xD;
      assessment will also be performed after 12 weeks of treatment.&#xD;
&#xD;
      Hypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR&#xD;
      provides greater improvements in glycemic, inflammatory and atherogenic parameters compared&#xD;
      to metformin monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 11, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glycosylated Hemoglobin (HbA1c) for metformin background patients</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline is calculated as the week 26 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage, the change from baseline is also a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glycosylated Hemoglobin (HbA1c) for treatment naive patients</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline is calculated as the week 26 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage, the change from baseline is also a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in acute insulin response to glucose (AIRg) for metformin background patients</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in acute insulin response to glucose at week 26</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in acute insulin response to glucose (AIRg) for treatment naive patients</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in acute insulin response to glucose at week 26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycosylated Hemoglobin (HbA1c) to &lt;7.0%</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline is calculated as the week 26 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage, the change from baseline is also a percentage. Percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c &lt;7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body weight</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in body weight at week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in fasting plasma glucose at week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Beta-cell function Index</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in beta cell function index at week 26. Beta-cell function Index is a measure of their capacity to respond to elevated blood glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin sensitivity index (ISI or Si)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in insulin sensitivity at week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated albumin (GA): glycosylated Hemoglobin A1c (HbA1c) ratio</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in glycosylated albumin (GA): glycosylated Hemoglobin A1c (HbA1c) at week 26. GA:HbA1c ratio provides a measure of post-prandial excursion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HOMA2-b%</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in HOMA of Beta-cell function index at week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HOMA-IR</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in HOMA-IR at week 26. HOMA-IR is a measure of insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin/Adiponectin ratio</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in Leptin/Adiponectin ratio. Indicator of insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Atherogenic Index (AI)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in Atherogenic Index at week 26. Atherogenic Index (AI) is a predictor of cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated albumin (GA)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in glycosylated albumin (GA) at week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Leptin</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in Leptin at week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Adiponectin</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in baseline in Adiponectin at week 26</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>High Blood Pressure</condition>
  <condition>Arthritis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Healthy adults with NGT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin-Drug naive patients &amp; Patients with inadequate glycemic control with Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive metformin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RK-01 Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive valsartan, celecoxib and metformin (low dose) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RK-01 High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive valsartan, celecoxib and metformin (high dose) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks</description>
    <arm_group_label>Metformin-Drug naive patients &amp; Patients with inadequate glycemic control with Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Val, Cel and Met XR Low</intervention_name>
    <description>500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.</description>
    <arm_group_label>RK-01 Low</arm_group_label>
    <other_name>Diovan</other_name>
    <other_name>Celebrex</other_name>
    <other_name>Glucophage XR</other_name>
    <other_name>RK-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Val, Cel and Met XR High</intervention_name>
    <description>1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.</description>
    <arm_group_label>RK-01 High</arm_group_label>
    <other_name>Diovan</other_name>
    <other_name>Celebrex</other_name>
    <other_name>Glucophage XR</other_name>
    <other_name>RK-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, Age: &gt;18 to 70 years at the time of screening visit.&#xD;
&#xD;
          2. Women of childbearing potential (WOCBP) must have negative serum or urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent of HCG) within 24 hours prior to the&#xD;
             start of the study.&#xD;
&#xD;
          3. Women must not be breastfeeding.&#xD;
&#xD;
          4. HbA1c≥8.0&#xD;
&#xD;
          5. Patients with inadequate blood glucose control with Metformin defined as a central&#xD;
             laboratory glycosylated hemoglobin (HbA1c) &gt;8.0 and &lt;10.5 obtained at the screening&#xD;
             visit. Metformin-HCl monotherapy was inadequate 3 months prior to the study as&#xD;
             indicated by the lack of decrease and/or an increase in the A1c level.&#xD;
&#xD;
             Newly diagnosed drug naïve patients as defined by HbA1c&gt;7.0 at the screening visit.&#xD;
             Drug naïve subjects diagnosed with type 2 diabetes within 6 months of diagnosis will&#xD;
             be considered and selected.&#xD;
&#xD;
             About half the patients are expected to be newly diagnosed in the study.&#xD;
&#xD;
          6. Drug naive as well as osteoarthritis patients with Type 2 diabetes receiving a&#xD;
             non-aspirin pain reliever (e.g. acetaminophen) or an NSAID (e.g. Naproxen).&#xD;
&#xD;
          7. Max/maintenance dose Metformin. Subjects should have been taking the same daily dose&#xD;
             of metformin for at least 8 weeks prior to the enrollment visit and subjects not&#xD;
             receive these other antihyperglycemic medications within the 12 weeks prior to&#xD;
             screening (except for short-term use of insulin [≤7 days] during concomitant illness&#xD;
             or other stress).&#xD;
&#xD;
          8. Patients with &gt;25% AIRg at 2 minutes and 10 minutes.&#xD;
&#xD;
          9. RAS blocker naïve patients&#xD;
&#xD;
         10. 2-Hour OGTT ≥200 mg/dL&#xD;
&#xD;
         11. FPG ≥140 mg/dL&#xD;
&#xD;
         12. BMI ≥30&#xD;
&#xD;
         13. Impaired first phase and second phase of insulin secretion&#xD;
&#xD;
         14. BP ≥140/90 mm Hg (These patients might be on an anti-hypertensive drug)&#xD;
&#xD;
         15. Non-fasting laboratory glucose &gt;200 mg/dL with symptoms of polydipsia, polyuria and/or&#xD;
             Polyphagia&#xD;
&#xD;
         16. eGFR ≥ 60 ml/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &gt;70&#xD;
&#xD;
          2. Patients with Type 1 diabetes, Screen for GAD (Glutamic acid decarboxylase) antibodies&#xD;
             at the time of screening visit. To rule out latent autoimmune diabetes in adults&#xD;
             (LADA), screening for other diabetes-related antibodies, such as insulinoma-associated&#xD;
             protein (IA-2 and IA-2 beta), zinc transporter-8 (ZnT8), islet cell antibodies (ICA)&#xD;
             or insulin autoantibody (IAA) will also be considered.&#xD;
&#xD;
          3. Pregnant women&#xD;
&#xD;
          4. Patients with a history of Ketoacidosis.&#xD;
&#xD;
          5. Subjects at serious risk of gastrointestinal (GI) adverse events (e.g. current or&#xD;
             recent history of GI bleeding ulceration, or perforation).&#xD;
&#xD;
          6. Subjects with a planned radiologic study with intravenous contrast, surgery, or other&#xD;
             planned procedures that may predispose them to metformin-associated lactic acidosis.&#xD;
&#xD;
          7. Insulin dependent: &lt;25% Beta-cell function: AIRg (Acute insulin response to glucose&#xD;
             after 2 min and 10 min after glucose injection) INSULIN DEPENDENT STATE.&#xD;
&#xD;
          8. Patients with a history of uncontrolled hyperglycemia &gt;15.0 mmol/L (280 mg/dL) after&#xD;
             an overnight fast that required rescue therapy.&#xD;
&#xD;
          9. Patients with uncontrolled hyperglycemia &gt;15.0 mmol/L (280 mg/dL) after an overnight&#xD;
             fast that required rescue therapy during week 1-3 Metformin-HCl monotherapy or RK-01&#xD;
             therapy.&#xD;
&#xD;
         10. eGFR, impaired kidney function &lt; 60 ml/min/1.73m2.&#xD;
&#xD;
         11. Poor metabolizers of Cyp450 2C9 to avoid very high concentration (Since Cytochrome 450&#xD;
             2C9 is responsible for the metabolism of both Valsartan and Celecoxib, patients who&#xD;
             are known or suspected to be poor Cyp450 2C9 metabolizers based on previous history&#xD;
             will be excluded from the study).&#xD;
&#xD;
         12. Any of the following cardiovascular (CV)/Vascular diseases within 3 months of the&#xD;
             enrollment visit:&#xD;
&#xD;
               1. Myocardial infarction (MI)&#xD;
&#xD;
               2. Cardiac surgery or revascularization (coronary artery bypass surgery, Coronary&#xD;
                  Artery Bypass Graft [(CABG]/Percutaneous transluminal coronary angioplasty&#xD;
                  (PTCA)].&#xD;
&#xD;
               3. Unstable angina&#xD;
&#xD;
               4. Unstable congestive heart failure (CHF)&#xD;
&#xD;
               5. Transient ischemic attack (TIA) or significant cerebrovascular disease&#xD;
&#xD;
               6. Unstable or previously diagnosed arrhythmia&#xD;
&#xD;
               7. Congestive heart failure, defined as New York Heart Association (NYHA) Class III&#xD;
                  and IV, unstable or acute heart failure and/or known left ventricular ejection&#xD;
                  fraction of ≤40%.&#xD;
&#xD;
               8. Acute coronary syndrome, stroke or transient ischemic attack within 3 months&#xD;
                  prior to the informed consent.&#xD;
&#xD;
         13. Previous bariatric surgery&#xD;
&#xD;
         14. Treatment with anti-obesity drugs within 3 months prior to consent&#xD;
&#xD;
         15. Patients with COPD&#xD;
&#xD;
         16. Patients with liver disease&#xD;
&#xD;
         17. Patients with renal disease&#xD;
&#xD;
         18. Patients with autoimmune diseases e.g. Lupus, Psoriasis&#xD;
&#xD;
         19. Patients with HIV/AIDS&#xD;
&#xD;
         20. Patients with diabetes-related complications&#xD;
&#xD;
         21. Patients with Hematological and Oncological Diseases/Conditions&#xD;
&#xD;
         22. Hemoglobin &lt;11.0 g/dL (110 g/L) for men; hemoglobin &lt;10.0 g/dL (100 g/L) for women&#xD;
&#xD;
         23. Patients with chronic disease e.g. Cancer, Epilepsy, Alzheimer, Parkinson, Asthma&#xD;
&#xD;
         24. Abnormal free T4&#xD;
&#xD;
         25. Patients with serious infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Kumar, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>ARKAY Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Busch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ravi Kumar, Ph.D.</last_name>
    <phone>(609) 977-1857</phone>
    <email>ravi.kumar@arkaytherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Busch, MD</last_name>
    <phone>(518) 461-9734</phone>
    <email>buschr@mail.amc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kevin Fiesthamel, MS</last_name>
      <phone>518-264-4472</phone>
      <email>feistht@amc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Spencer Phelps, CCRC</last_name>
      <phone>518-264-4474</phone>
      <email>phelpss2@amc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Busch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grimm Loretta, FNP-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Obesity</keyword>
  <keyword>FPG</keyword>
  <keyword>Beta cell function index</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Atherogenic index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Study results will be published on clinicaltrials.gov as well as a medical journal. We also plan to present the results at a conference such as American Diabetes Association's Scientific Sessions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

